Victory Capital Management Inc. Acquires 21,530 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Victory Capital Management Inc. increased its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 10.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 218,531 shares of the company's stock after buying an additional 21,530 shares during the quarter. Victory Capital Management Inc. owned approximately 0.45% of Amphastar Pharmaceuticals worth $10,605,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. ProShare Advisors LLC raised its stake in Amphastar Pharmaceuticals by 6.9% in the first quarter. ProShare Advisors LLC now owns 10,973 shares of the company's stock valued at $482,000 after buying an additional 708 shares during the period. UniSuper Management Pty Ltd bought a new position in Amphastar Pharmaceuticals during the first quarter worth $296,000. CANADA LIFE ASSURANCE Co increased its holdings in shares of Amphastar Pharmaceuticals by 29.3% in the first quarter. CANADA LIFE ASSURANCE Co now owns 39,930 shares of the company's stock valued at $1,752,000 after purchasing an additional 9,037 shares during the last quarter. Epoch Investment Partners Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 34.8% during the 1st quarter. Epoch Investment Partners Inc. now owns 798,462 shares of the company's stock worth $35,060,000 after buying an additional 205,932 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 35.1% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company's stock worth $4,937,000 after buying an additional 29,182 shares during the period. 65.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Floyd F. Petersen sold 3,000 shares of the firm's stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the completion of the transaction, the director now owns 75,409 shares in the company, valued at $3,504,256.23. This trade represents a 3.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Rong Zhou sold 4,000 shares of Amphastar Pharmaceuticals stock in a transaction on Monday, August 26th. The stock was sold at an average price of $48.35, for a total transaction of $193,400.00. Following the transaction, the executive vice president now owns 118,388 shares in the company, valued at approximately $5,724,059.80. This trade represents a 3.27 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 31,533 shares of company stock worth $1,571,652 in the last ninety days. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH opened at $44.09 on Thursday. The firm's 50 day simple moving average is $48.38 and its 200 day simple moving average is $44.42. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of 14.70, a P/E/G ratio of 0.89 and a beta of 0.82.

Analysts Set New Price Targets

AMPH has been the subject of a number of research analyst reports. StockNews.com cut Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, November 1st. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Finally, Piper Sandler reduced their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating on the stock in a research report on Thursday, August 8th.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.